###begin article-title 0
###xml 30 33 30 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGT</italic>
The M235T Polymorphism in the AGT Gene and CHD Risk: Evidence of a Hardy-Weinberg Equilibrium Violation and Publication Bias in a Meta-Analysis
###end article-title 0
###begin p 1
Conceived and designed the experiments: MZ MB Yv DG. Performed the experiments: Pd Yv. Analyzed the data: MZ MB. Contributed reagents/materials/analysis tools: MZ MB. Wrote the paper: MZ MB Pd Yv DG.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 30 33 30 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGT</italic>
The M235T polymorphism in the AGT gene has been related to an increased risk of hypertension. This finding may also suggest an increased risk of coronary heart disease (CHD).
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 484 485 484 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 488 492 488 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0.28</italic>
###xml 571 572 571 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 575 579 575 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0.38</italic>
###xml 798 799 798 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 802 806 802 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0.20</italic>
###xml 1147 1148 1147 1148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1151 1155 1151 1155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0.02</italic>
###xml 1477 1478 1477 1478 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1517 1518 1517 1518 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 64 69 <span type="species:ncbi:9606">women</span>
###xml 165 170 <span type="species:ncbi:9606">women</span>
A case-cohort study was conducted in 1,732 unrelated middle-age women (210 CHD cases and 1,522 controls) from a prospective cohort of 15,236 initially healthy Dutch women. We applied a Cox proportional hazards model to study the association of the polymorphism with acute myocardial infarction (AMI) (n = 71) and CHD. In the case-cohort study, no increased risk for CHD was found under the additive genetic model (hazard ratio [HR] = 1.20; 95% confidence interval [CI], 0.86 to 1.68; P = 0.28). This result was not changed by adjustment (HR = 1.17; 95% CI, 0.83 to 1.64; P = 0.38) nor by using dominant, recessive and pairwise genetic models. Analyses for AMI risk under the additive genetic model also did not show any statistically significant association (crude HR = 1.14; 95% CI, 0.93 to 1.39; P = 0.20). To evaluate the association, a comprehensive systematic review and meta-analysis were undertaken of all studies published up to February 2007 (searched through PubMed/MEDLINE, Web of Science and EMBASE). The meta-analysis (38 studies with 13284 cases and 18722 controls) showed a per-allele odds ratio (OR) of 1.08 (95% CI, 1.01 to 1.15; P = 0.02). Moderate to large levels of heterogeneity were identified between studies. Hardy-Weinberg equilibrium (HWE) violation and the mean age of cases were statistically significant sources of the observed variation. In a stratum of non-HWE violation studies, there was no effect. An asymmetric funnel plot, the Egger's test (P = 0.066), and the Begg-Mazumdar test (P = 0.074) were all suggestive of the presence of publication bias.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
###xml 170 173 170 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGT</italic>
The pooled OR of the present meta-analysis, including our own data, presented evidence that there is an increase in the risk of CHD conferred by the M235T variant of the AGT gene. However, the relevance of this weakly positive overall association remains uncertain because it may be due to various residual biases, including HWE-violation and publication biases.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 503 506 503 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Jeunemaitre1">[1]</xref>
###xml 545 548 545 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGT</italic>
###xml 787 790 787 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Jeunemaitre1">[1]</xref>
###xml 791 794 791 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Paillard1">[3]</xref>
###xml 975 978 975 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Staessen1">[4]</xref>
###xml 706 714 <span type="species:ncbi:9606">patients</span>
###xml 904 910 <span type="species:ncbi:9606">people</span>
###xml 932 938 <span type="species:ncbi:9606">people</span>
Angiotensinogen (AGT) is a liver protein that interacts with renin to produce angiotensin I, the pro-hormone of angiotensin II. Angiotensin II is the major effector molecule of the renin-angiotensin-aldosterone system (RAAS) and plays a key role in the regulation of blood pressure (BP) by increasing vascular tone and promoting sodium retention. Genetic variants in the angiotensinogen gene modify the plasma concentration of angiotensinogen, which has been directly related to arterial blood pressure [1]. The molecular variant (M235T) of the AGT gene, encoding a threonine instead of a methionine at residue 235 of the mature protein, has been associated with a higher plasma AGT level and higher BP in patients homozygous for the T allele and occurs among various ethnic populations [1]-[3]. In a meta-analysis, the TT genotype was associated with a 32% increase in the risk of hypertension in white people but not in non-white people, when compared with the MM genotype [4].
###end p 9
###begin p 10
###xml 81 84 81 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Sattar1">[5]</xref>
###xml 186 189 186 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Ludwig1">[6]</xref>
###xml 190 193 190 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-RodriguezPerez1">[8]</xref>
###xml 226 229 226 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Lanz1">[9]</xref>
###xml 231 235 231 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Sekuri1">[10]</xref>
###xml 289 292 289 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGT</italic>
###xml 396 400 396 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Nair1">[11]</xref>
###xml 401 405 401 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Tiret1">[13]</xref>
###xml 436 440 436 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Sethi2">[14]</xref>
###xml 719 722 719 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGT</italic>
###xml 927 932 <span type="species:ncbi:9606">women</span>
Given the importance of hypertension in the occurrence of coronary heart disease [5], this finding suggests that this polymorphism may be related to increased risk of CHD. A few studies [6]-[8], including recent publications, [9], [10] have found that there is an association of the M235T AGT variant with increased CHD risk; however, this relationship was not confirmed in several other studies [11]-[13] as well as in a meta-analysis [14]. Marked ethnic differences in the frequency of the T allele, small sample sizes and genotyping or phenotyping errors could partly account for discrepancies among these gene-disease association studies. Therefore, we investigated the association of the M235T polymorphism in the AGT gene (National Center for Biotechnology Information single nucleotide polymorphism cluster ID rs699) with acute myocardial infarction (AMI) and CHD in a large population-based cohort of middle-aged Dutch women and conducted an updated meta-analysis of the available studies to clarify the role of the M235T polymorphism in CHD risk.
###end p 10
###begin title 11
Methods
###end title 11
###begin title 12
Case-cohort study
###end title 12
###begin p 13
###xml 120 124 120 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Boker1">[15]</xref>
###xml 125 129 125 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Zafarmand1">[16]</xref>
###xml 174 186 <span type="species:ncbi:9606">participants</span>
###xml 216 228 <span type="species:ncbi:9606">Participants</span>
###xml 272 277 <span type="species:ncbi:9606">women</span>
###xml 407 412 <span type="species:ncbi:9606">women</span>
###xml 1183 1188 <span type="species:ncbi:9606">women</span>
Study design, general questionnaire, anthropometric and laboratory measurements have been described in detail elsewhere [15]-[16]. Briefly, the study population consisted of participants of the Prospect-EPIC cohort. Participants were recruited between 1993 and 1997 among women living in Utrecht and the vicinity who attended the regional population-based breast cancer-screening program. A total of 17,357 women, aged 49-70, were included. At baseline, a general and a dietary questionnaire were administered, a limited physical examination was performed and a non-fasting blood sample was taken. Follow-up event information was obtained from the Dutch Centre for Health Care Information, which holds a standardized computerized register of hospital discharge diagnoses. Using the International Classification of Diseases, ninth Revision (ICD-9) codes for the main discharge reason, we categorized cardiovascular disease (codes 390-459) as CHD (codes 410-414), including AMI (code 410), and other cardiovascular diseases. Whenever multiple events (AMI and CHD) occurred, the first occurrence of that endpoint was taken as the endpoint of interest in endpoint-specific analyses. All women signed an informed consent form prior to study inclusion. The study was approved by the Institutional Review Board of the University Medical Center Utrecht.
###end p 13
###begin p 14
###xml 57 61 57 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Prentice1">[17]</xref>
###xml 714 716 714 716 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">st</sup>
###xml 79 84 <span type="species:ncbi:9606">women</span>
###xml 173 178 <span type="species:ncbi:9606">Women</span>
###xml 316 321 <span type="species:ncbi:9606">Women</span>
###xml 498 503 <span type="species:ncbi:9606">women</span>
###xml 533 538 <span type="species:ncbi:9606">women</span>
We applied the case-cohort design introduced by Prentice [17]. From the 17,357 women in the total cohort, we randomly selected a sample of 10% as the sub-cohort (n = l736). Women who did not consent to linkage with vital status registries or who were not traceable (cases n = 3/sub-cohort n = 38) were not included. Women who reported a diagnosis of cardiovascular disease (ICD-9; 390-459) at baseline or who had missing questionnaires, blood, or DNA samples were excluded. This resulted in 15,236 women in the total cohort and 1522 women in the sub-cohort (as the control group) at baseline. All individuals with first fatal and non-fatal CHD and ischemic stroke events that arose during follow-up until January 1st 2000 were selected as cases. These were 211 CHD cases, including 71 AMIs. For all case subjects, follow-up ended at the date of diagnosis or at the date of death due to cardiovascular disease.
###end p 14
###begin title 15
Genetic analysis
###end title 15
###begin p 16
###xml 462 466 460 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Cheng1">[18]</xref>
Genetic analysis was performed at the Cardiovascular Genotyping (CAGT) laboratory of the Department of Internal Medicine of the University Hospital Maastricht. Genomic DNA was extracted from buffy coats using the QIAamp(R) Blood Kit (Qiagen Inc., Valencia, California, USA). Genotyping of the polymorphisms was performed using a multilocus genotyping assay for candidate markers of cardiovascular disease risk (Roche Molecular Systems Inc., Pleasanton, CA, USA) [18]. Briefly, each DNA sample was amplified using two multiplex polymerase chain reactions, and the alleles were genotyped simultaneously using an array of immobilized sequence-specific oligonucleotide probes. This array of probes was blotted on plastic strips, and, after staining, genotypes were scored based on blue (positive) and white (negative) bands. Each blue band, representing a specific genotype, was scored by specific software (counting the pixel intensity of each band) and checked manually. Genotyping was performed blinded to the case-control status. A random double-check was performed to detect potential genotyping errors in a subset of 100 samples. The check confirmed the previous genotyping results by 100%.
###end p 16
###begin title 17
Data analysis
###end title 17
###begin p 18
###xml 56 57 54 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 153 154 151 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 323 324 319 320 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Hardy-Weinberg equilibrium (HWE) was tested with the chi2 test among the controls. Allele frequencies were estimated by gene counting. We used the ANOVA F test to estimate relationships among the M235T genotypes and continuous variables, while we tested the significance of any difference in proportions by applying the chi2 statistic. A p-value <0.05 (2-sided) was considered statistically significant.
###end p 18
###begin p 19
###xml 60 63 60 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGT</italic>
###xml 232 236 232 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Prentice1">[17]</xref>
###xml 238 242 238 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-OnlandMoret1">[19]</xref>
###xml 311 315 311 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Sethi2">[14]</xref>
###xml 346 349 346 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGT</italic>
###xml 626 632 626 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">priori</italic>
###xml 707 710 707 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGT</italic>
###xml 899 930 899 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">the additive &#8220;per-allele&#8221; model</italic>
###xml 1116 1135 1116 1135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">the recessive model</italic>
###xml 1198 1216 1198 1216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">the dominant model</italic>
To assess the relationship of the M235T polymorphism in the AGT gene with the outcome, we used a Cox proportional hazards model with an estimation procedure adapted for case-cohort designs. We used the unweighted method by Prentice [17], [19], which is incorporated in a SAS macro at . A previous meta-analysis [14] showed that the effect of the AGT M235T variant on its intermediate phenotype (plasma angiotensinogen level) follows an additive model according to the number of T alleles [5% (95% CI: 2 to 8%) increase for the MT and 11% (95% CI: 7 to 15%) increase for the TT genotype versus the MM genotype]. Therefore, our priori hypothesis was that the association between the M235T polymorphism in the AGT gene and CHD follows an additive model according to the number of T alleles. However, other genetic models were evaluated as well. We considered different modes of inheritance as follows: the additive "per-allele" model, the T allele was compared between cases and controls by assigning scores of 0, 1, and 2 to homozygotes for the M allele, heterozygotes, and homozygotes for the T allele, respectively; the recessive model, the TT genotype versus the MT and MM combined genotypes; and the dominant model, the MT and TT genotypes combined versus the MM genotype. We also performed separate pairwise comparisons of the MT and TT genotypes versus the MM genotype.
###end p 19
###begin title 20
Meta-analysis
###end title 20
###begin title 21
Searching
###end title 21
###begin p 22
###xml 165 168 165 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGT</italic>
###xml 324 327 324 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGT</italic>
###xml 879 884 <span type="species:ncbi:9606">human</span>
We searched PubMed/MEDLINE, Web of Science, and EMBASE up to February 2007 for observational studies evaluating an association between the M235T polymorphism in the AGT gene and CHD. Terms used for the search contained both medical subject heading terms and text words: (Met235Thr OR M235T OR T704C) AND (angiotensinogen OR AGT) AND (polymorphism OR mutation OR genetic OR genotype) AND ("coronary disease" OR "coronary heart disease" OR CHD OR "myocardial infarction" OR MI OR "myocardial infarct" OR "coronary artery disease" OR CAD OR "ischemic heart disease" OR IHD OR "cardiovascular disease" OR "heart disease" OR angina). We also retrieved additional studies by hand searching the bibliographies of original research reports and review articles and through the MEDLINE option "related articles". Search results were limited to articles published in English and studies on human subjects.
###end p 22
###begin title 23
Selection
###end title 23
###begin p 24
###xml 256 259 256 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGT</italic>
All studies were considered potentially eligible if they aimed to investigate the relationship between the M235T genotypes and risk of CHD or MI. Any observational study, regardless of sample size, which fulfilled the following criteria, was included: (i) AGT M235T genotype frequencies were provided by case-control status (studies without controls were excluded); (ii) risk of CHD or MI was evaluated (studies on recurrent coronary events were excluded); (iii) relevant data were presented to calculate the effect size and its 95% CI; (iv) non-overlapping data were contained. For duplicate publications, the study with the smaller data set was excluded.
###end p 24
###begin title 25
Data abstraction
###end title 25
###begin p 26
###xml 757 760 757 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGT</italic>
###xml 200 208 <span type="species:ncbi:9606">patients</span>
###xml 321 329 <span type="species:ncbi:9606">patients</span>
The following information was extracted from each study that we included: the first author's name; country; year of publication; the population evaluated; study design; mean age or age range for case-patients and controls; definition and number of cases and controls; allele frequencies and genotype distribution in case-patients and controls (where data were not given, they were calculated from the corresponding genotyping frequencies of the case and control groups); consistency of genotype frequencies with HWE (calculated); gender in the evaluated population and male percentage, matching variables, use of blinding of genotyping staff, performing regenotyping of a random sample, and crude ORs and 95% CIs for development of CHD or MI related to the AGT gene genotypes based on different genetic models (from the original paper or calculated from crude data if not provided). We again considered a dominant, a recessive, an additive "per-allele" model and pairwise comparisons. Data were extracted independently and entered into separate databases by two authors (performed by MHZ and MLB). Results were compared, and disagreements were resolved by a consensus.
###end p 26
###begin title 27
Quantitative data synthesis
###end title 27
###begin p 28
###xml 474 480 474 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">priori</italic>
###xml 565 566 563 564 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 649 653 647 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Trikalinos1">[20]</xref>
The method of Mantel-Haenszel was used to calculate the odds ratio for the pooled data in a fixed-effects model, and, if there was evidence for heterogeneity, the DerSimonian-Laird method was used for the pooled odds ratio in a random-effects model, under pairwise comparisons of the different genotypes and dominant, recessive, and additive inheritance models. For all the models used, the T allele was considered the risk allele. The genetic model to be considered as the priori hypothesis was the additive model. In each study, we tested for HWE by using the chi2 test or an exact test among the controls by using the genhwi command in Stata 9.2 [20].
###end p 28
###begin p 29
###xml 34 35 32 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 44 45 42 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Q</italic>
###xml 44 45 42 43 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>Q</italic></bold>
###xml 131 132 129 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 155 156 153 154 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 154 156 152 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I<sup>2</sup></italic>
###xml 154 156 152 154 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>I<sup>2</sup></italic></bold>
###xml 216 220 214 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Trikalinos1">[20]</xref>
###xml 223 224 221 222 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 222 224 220 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I<sup>2</sup></italic>
###xml 222 224 220 222 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>I<sup>2</sup></italic></bold>
###xml 534 535 532 533 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 533 535 531 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I<sup>2</sup></italic>
###xml 533 535 531 533 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>I<sup>2</sup></italic></bold>
###xml 564 565 562 563 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 563 565 561 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I<sup>2</sup></italic>
###xml 563 565 561 563 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>I<sup>2</sup></italic></bold>
###xml 601 602 599 600 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 600 602 598 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I<sup>2</sup></italic>
###xml 600 602 598 600 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>I<sup>2</sup></italic></bold>
###xml 635 636 633 634 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 634 636 632 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I<sup>2</sup></italic>
###xml 634 636 632 634 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>I<sup>2</sup></italic></bold>
###xml 671 675 669 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Higgins1">[21]</xref>
In addition, we used Cochran's chi2 - based Q statistic for between-study heterogeneity, which is considered to be significant for P<0.10, as well as the I2 statistic for estimation of inconsistency in meta-analyses [20]. I2 represents the percentage of the observed between-study variability due to heterogeneity rather than to chance. It ranges between 0% and 100%, where a value of 0% indicates no observed heterogeneity, and larger values indicate an increasing degree of heterogeneity (roughly suggested cut-off points include: I2 = 0-25%, no heterogeneity; I2 = 25-50%, moderate heterogeneity; I2 = 50-75%, large heterogeneity; I2 = 75-100%, extreme heterogeneity) [21].
###end p 29
###begin p 30
###xml 223 224 223 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 606 610 606 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-AgerholmLarsen1">[22]</xref>
We used funnel plots to examine the publication bias of reported associations. We also used Egger's test and the Begg-Mazumdar test with 95% CI for evaluation of publication bias, which are considered to be significant for P<0.10. Meta-analysis was carried out using STATA 9.2. We used random effect meta-regression models with restricted maximum likelihood estimation to evaluate the extent to which different variables explained heterogeneity among the individual ORs. The pre-specified characteristics for assessment of sources of inter-study heterogeneity were: study size (for detailed definition see [22]); ethnicity of population evaluated (of Caucasian descent, East Asian, and others); male percentage in each study, matching (matched or unmatched); blinding of genotyping staff (blinded, or not reported); performing regenotyping of a random sample (performed or not reported); violating HWE (violated or confirmed; the term "violated" used for statistically significant deviation of HWE) in sub-group analysis as well as in meta-regression analysis.
###end p 30
###begin title 31
HWE Correction
###end title 31
###begin p 32
###xml 290 294 290 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Trikalinos1">[20]</xref>
For evaluating the impact of HWE-violated studies on effect estimates (at the 0.05 significance level) under different genetic models, odds ratios, and variances were corrected by using the HWE-predicted genotype counts in the control instead of the observed counts as previously suggested [20]. Thereafter, they were included in the sensitivity analysis.
###end p 32
###begin title 33
Results
###end title 33
###begin title 34
Prospect-EPIC study results
###end title 34
###begin p 35
###xml 103 110 103 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002533-t001">Table 1</xref>
###xml 176 177 174 175 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 180 185 178 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0.020</italic>
###xml 187 188 185 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 191 195 189 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0.89</italic>
###xml 274 281 272 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002533-t001">Table 1</xref>
###xml 52 64 <span type="species:ncbi:9606">participants</span>
###xml 368 374 <span type="species:ncbi:9606">person</span>
###xml 436 441 <span type="species:ncbi:9606">women</span>
###xml 453 459 <span type="species:ncbi:9606">person</span>
###xml 501 506 <span type="species:ncbi:9606">women</span>
The general characteristics of the randomly sampled participants of the cohort (N = 1522) are given in Table 1. The genotype distribution was in Hardy-Weinberg equilibrium (chi2 = 0.020; P = 0.89). General and clinical characteristics of CHD cases and controls are shown in Table 1. The median follow up time for the random sample was 4.3 years, with a total of 6,523 person years. The actual follow-up in the baseline cohort of 15,236 women was 64,768 person years. Due to the case-cohort design, 23 women in the sub-cohort eventually were CHD cases (among which there were nine AMI cases).
###end p 35
###begin title 36
Baseline characteristics of the sub-cohort according to genotype, and clinical characteristics of CHD cases and controls in the Prospect -Epic cohort.
###end title 36
###begin p 37
HDL, high-density lipoprotein; LDL, low-density lipoprotein; CHD, coronary heart disease (ICD 410-414).
###end p 37
###begin p 38
Mean+/-standard deviation.
###end p 38
###begin p 39
###xml 61 62 61 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 102 103 100 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Comparison of risk factors across genotypes, using the ANOVA F test (continuous variables) and the chi2 statistic (categorical variables).
###end p 39
###begin p 40
###xml 60 86 60 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">independent samples t-test</italic>
###xml 121 122 119 120 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Comparison of risk factors across disease status, using the independent samples t-test (continuous variables) and the chi2 statistic (categorical variables).
###end p 40
###begin p 41
Defined as a systolic blood pressure >/=140 mm Hg and/or diastolic blood pressure >/=90 mm Hg and/or questionnaire positive.
###end p 41
###begin p 42
###xml 76 82 <span type="species:ncbi:9606">person</span>
The number of packs of cigarettes smoked per day by the number of years the person has smoked.
###end p 42
###begin p 43
###xml 216 223 216 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002533-t002">Table 2</xref>
###xml 405 406 405 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 409 413 409 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0.28</italic>
###xml 487 488 487 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 491 495 491 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0.38</italic>
###xml 539 546 539 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002533-t002">Table 2</xref>
###xml 628 635 628 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002533-t002">Table 2</xref>
Due to the association of the M235T genotypes with some risk factors of CHD, we presented crude models and models adjusted for hypertension, total cholesterol and waist to hip ratio as potential confounding factors. Table 2 presents hazard ratios of AMI and CHD under different genetic models. Under the additive model of inheritance, no increased risk for CHD was found (HR = 1.20; 95% CI, 0.86 to 1.68; P = 0.28), which did not alter after adjustment (HR = 1.17; 95% CI, 0.83 to 1.64; P = 0.38). The same was true for other comparisons (Table 2). Analyses for AMI risk did not show any statistically significant associations (Table 2).
###end p 43
###begin title 44
###xml 19 22 19 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGT</italic>
Association of the AGT M235T polymorphism and AMI and CHD under different genetic models.
###end title 44
###begin p 45
AMI = acute myocardial infarction (ICD 410); CHD = coronary heart disease (ICD 410-414).
###end p 45
###begin p 46
The additive genetic model assumes that there is a linear gradient in risk between the MM, MT and TT genotypes (MM genotype baseline). This is equivalent to a comparison of the T allele versus the M allele (baseline).
###end p 46
###begin p 47
We used a cox proportional hazards model with an estimation procedure adapted for case-cohort designs; adjusted for waist to hip ratio, hypertension, total cholesterol.
###end p 47
###begin title 48
Meta-Analysis results
###end title 48
###begin p 49
###xml 0 24 0 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Flow of included studies</italic>
###xml 0 24 0 24 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>Flow of included studies</italic></bold>
###xml 118 121 118 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGT</italic>
###xml 244 248 244 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Sethi1">[12]</xref>
###xml 250 254 250 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Berdeli1">[23]</xref>
###xml 256 260 256 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-FernandezArcas1">[24]</xref>
###xml 307 311 307 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Zee1">[25]</xref>
###xml 312 316 312 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Krizanova1">[27]</xref>
###xml 381 385 381 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Goldenberg1">[28]</xref>
###xml 506 509 506 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Ludwig1">[6]</xref>
###xml 657 665 657 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002533-g001">Figure 1</xref>
Flow of included studies. A total of 44 gene-disease association studies, including the present study, evaluating the AGT M235T gene variant and CHD risk were identified. Seven articles were excluded, three of which were duplicate publications [12], [23], [24], three of which did not provide relevant data [25]-[27], and one of which studied the risk of recurrent coronary events [28]. Finally, 37 studies met the selection criteria. In one paper, the provided results were based on two different studies [6], so both were included in the meta-analysis. Therefore, 38 studies with 13,284 cases and 18,722 controls were included in the final meta-analysis (Figure 1).
###end p 49
###begin title 50
Flow chart of study selection.
###end title 50
###begin title 51
Study characteristics
###end title 51
###begin p 52
###xml 44 51 44 51 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002533-t003">Table 3</xref>
###xml 51 54 51 54 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Ludwig1">[6]</xref>
###xml 55 58 55 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-RodriguezPerez1">[8]</xref>
###xml 60 64 60 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Sekuri1">[10]</xref>
###xml 66 70 66 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Nair1">[11]</xref>
###xml 72 76 72 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Tiret1">[13]</xref>
###xml 78 82 78 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Sethi3">[29]</xref>
###xml 83 87 83 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-YamakawaKobayashi1">[58]</xref>
###xml 417 421 417 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Wierzbicki1">[56]</xref>
###xml 472 476 472 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Gardemann1">[40]</xref>
Characteristics of the studies are shown in Table 3[6]-[8], [10], [11], [13], [29]-[58]. There were 25 studies in Caucasians, eight studies in East Asians, and five studies in other populations (West Asian, South Asian, African, African-American, and South American). The last was collapsed into a miscellaneous group. The design of the studies was case-control, except for three studies that were prospective cohort [56], case-cohort (present study), and cross-sectional [40]. The T allele frequency varied from 26 to 54 percent in Caucasians, 65 to 91 percent in East Asians, and 34 to 83 percent in the miscellaneous group.
###end p 52
###begin title 53
###xml 90 93 90 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGT</italic>
Characteristics of published studies of the association between the M235T polymorphism in AGT gene and CHD included in the meta-analysis.
###end title 53
###begin p 54
PTCA, percutaneous coronary angioplasty; CABG, coronary artery bypass graft; ICD, international classification of diseases; ECG, electrocardiography; AMI, acute myocardial infarction; CHD, coronary heart disease; CVD, cardiovascular diseases; CVA, cerebrovascular accident; BMI, body mass index; WHO, world health organization; NR, not reported.
###end p 54
###begin p 55
Exact significance probability.
###end p 55
###begin p 56
###xml 282 285 282 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-RodriguezPerez1">[8]</xref>
###xml 287 291 287 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Bis1">[32]</xref>
###xml 293 297 293 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Reinhardt1">[50]</xref>
###xml 299 303 299 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Renner1">[51]</xref>
###xml 305 309 305 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Wierzbicki1">[56]</xref>
###xml 401 405 401 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-FernandezArcas2">[37]</xref>
###xml 407 411 407 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Reinhardt1">[50]</xref>
###xml 413 417 413 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Tobin1">[53]</xref>
###xml 419 423 419 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Wierzbicki1">[56]</xref>
###xml 583 590 583 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002533-t003">Table 3</xref>
###xml 592 596 592 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Buraczynska1">[33]</xref>
###xml 598 602 598 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Cong1">[34]</xref>
###xml 604 608 604 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Fatini1">[36]</xref>
###xml 610 614 610 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Ishigami1">[43]</xref>
###xml 616 620 616 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Reinhardt1">[50]</xref>
###xml 710 713 710 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Olivieri1">[7]</xref>
###xml 715 718 715 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-RodriguezPerez1">[8]</xref>
###xml 720 724 720 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Sekuri1">[10]</xref>
###xml 726 730 726 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Nair1">[11]</xref>
###xml 732 736 732 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Cong1">[34]</xref>
###xml 738 742 738 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Gardemann1">[40]</xref>
###xml 744 748 744 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Hooper1">[41]</xref>
###xml 750 754 750 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Ishigami1">[43]</xref>
###xml 756 760 756 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Ko1">[46]</xref>
###xml 762 766 762 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Ortlepp1">[48]</xref>
###xml 768 772 768 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Reinhardt1">[50]</xref>
###xml 774 778 774 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Renner1">[51]</xref>
###xml 780 784 780 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Tsai1">[54]</xref>
###xml 785 789 785 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Winkelmann1">[57]</xref>
###xml 846 850 846 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Fatini1">[36]</xref>
###xml 852 856 852 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Ichihara1">[42]</xref>
###xml 858 862 858 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Sheu1">[52]</xref>
###xml 864 868 864 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-YamakawaKobayashi1">[58]</xref>
###xml 884 888 884 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Tiret1">[13]</xref>
###xml 890 894 890 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Sethi3">[29]</xref>
###xml 895 899 895 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Bis1">[32]</xref>
###xml 901 905 901 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Ermis1">[35]</xref>
###xml 907 911 907 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-FernandezArcas2">[37]</xref>
###xml 912 916 912 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Frossard1">[39]</xref>
###xml 918 922 918 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Kamitani1">[44]</xref>
###xml 924 928 924 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Methot1">[47]</xref>
###xml 930 934 930 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Ranjith1">[49]</xref>
###xml 936 940 936 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Tobin1">[53]</xref>
###xml 1040 1043 1040 1043 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Ludwig1">[6]</xref>
###xml 1045 1049 1045 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Buraczynska1">[33]</xref>
###xml 1051 1055 1051 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Katsuya1">[45]</xref>
###xml 1126 1129 1126 1129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Ludwig1">[6]</xref>
###xml 1131 1134 1131 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-RodriguezPerez1">[8]</xref>
###xml 1136 1140 1136 1140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Tiret1">[13]</xref>
###xml 1142 1146 1142 1146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Sethi3">[29]</xref>
###xml 1148 1152 1148 1152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Batalla1">[31]</xref>
###xml 1153 1157 1153 1157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Buraczynska1">[33]</xref>
###xml 1159 1163 1159 1163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Ermis1">[35]</xref>
###xml 1164 1168 1164 1168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Fomicheva1">[38]</xref>
###xml 1170 1174 1170 1174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Katsuya1">[45]</xref>
###xml 1176 1180 1176 1180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Methot1">[47]</xref>
###xml 1182 1186 1182 1186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Ranjith1">[49]</xref>
###xml 1187 1191 1187 1191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Tobin1">[53]</xref>
###xml 1193 1197 1193 1197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Wenzel1">[55]</xref>
###xml 1274 1277 1274 1277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Olivieri1">[7]</xref>
###xml 1279 1283 1279 1283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Sekuri1">[10]</xref>
###xml 1285 1289 1285 1289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Nair1">[11]</xref>
###xml 1291 1295 1291 1295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Araujo1">[30]</xref>
###xml 1297 1301 1297 1301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Cong1">[34]</xref>
###xml 1303 1307 1303 1307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Frossard1">[39]</xref>
###xml 1308 1312 1308 1312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Kamitani1">[44]</xref>
###xml 1314 1318 1314 1318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Ko1">[46]</xref>
###xml 1320 1324 1320 1324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Ortlepp1">[48]</xref>
###xml 1326 1330 1326 1330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Tsai1">[54]</xref>
###xml 1332 1336 1332 1336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Wierzbicki1">[56]</xref>
###xml 1337 1341 1337 1341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-YamakawaKobayashi1">[58]</xref>
###xml 241 253 <span type="species:ncbi:9606">participants</span>
All studies used polymerase chain reaction methods for genotyping, and most used a restriction fragment length method for polymorphism analysis. Blinding of investigators involved in genotyping with respect to the case/control status of the participants was reported in six studies [8], [32], [50], [51], [56]. A random double-check to detect potential genotyping errors was mentioned in five studies [37], [50], [53], [56]. In most of the studies, the genotype frequencies were consistent with HWE. However, statistically significant deviations from HWE were found in five studies (Table 3) [33], [34], [36], [43], [50]. CHD cases were defined in 16 studies as a >50% stenosis of at least one coronary vessel [7], [8], [10], [11], [34], [40], [41], [43], [46], [48], [50], [51], [54]-[57], while, in four studies, a >70% stenosis was considered [36], [42], [52], [58]. In 14 studies [13], [29]-[32], [35], [37]-[39], [44], [47], [49], [53], the WHO criteria were used, and, in four studies, CHD was diagnosed based on a clinical diagnosis [6], [33], [45]. Controls arose from the source population of the cases in 21 studies [6], [8], [13], [29], [31]-[33], [35]-[38], [45], [47], [49]-[53], [55], while hospital-based/not population-based controls were used in 17 studies [7], [10], [11], [30], [34], [39]-[44], [46], [48], [54], [56]-[58].
###end p 56
###begin title 57
Quantitative data synthesis
###end title 57
###begin p 58
###xml 113 114 113 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 124 132 124 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002533-g002">Figure 2</xref>
###xml 208 209 208 209 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 207 209 207 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I<sup>2</sup></italic>
###xml 207 209 207 209 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>I<sup>2</sup></italic></bold>
###xml 219 220 219 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 229 236 229 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002533-t004">Table 4</xref>
###xml 266 269 266 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGT</italic>
###xml 567 568 567 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 824 825 824 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 923 930 923 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002533-t004">Table 4</xref>
###xml 1336 1343 1336 1343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002533-t005">Table 5</xref>
The overall OR under a random-effects model using an additive model for CHD risk was 1.08 (95% CI, 1.01 to 1.15; P = 0.025; Figure 2). However, there was evidence of substantial between-study heterogeneity (I2 = 55.5%, P<0.001). Table 4 shows the association of the AGT T235M polymorphism with CHD risk under different genetic contrasts. When a recessive model was evaluated, a significant association was found between individuals homozygous for the T allele (T235T genotype) and CHD risk, when compared to carriers of the M allele (OR = 1.11; 95% CI, 1.02 to 1.22; P = 0.016). Under the dominant model, the association was not significant. Under pairwise comparisons, there was a significant modest association between the T235T genotype and CHD risk, as compared with the M235M genotype (OR = 1.15; 95% CI, 1.00 to 1.32; P = 0.045). There was evidence for moderate to large between-study heterogeneity under all models (Table 4). Sub-group analysis, by study characteristics under the additive model, showed that matching, blinding of genotyping staff, and regenotyping of a random sub-sample explained little of the heterogeneity. However, stratification showed an attenuated effect estimates in the large studies, in studies that CHD was defined based on angiography or WHO criteria, and in particular in studies that were in HWE (Table 5). Further evaluation of potential sources of the heterogeneity was performed using a meta-regression analysis.
###end p 58
###begin title 59
###xml 78 81 78 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGT</italic>
Results of published studies of association between the M235T polymorphism in AGT gene and coronary heart disease in different ethnic groups.
###end title 59
###begin p 60
###xml 153 154 153 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
ORs for the outcome compared the T235 allele vs. the M235 allele (Additive model). The size of the box is proportional to the weight of the study. Given P-values for odds ratios are based on DerSimonian-Laird method using a random effects model and for heterogeneity in different ethnic groups are based on Q-test.
###end p 60
###begin title 61
###xml 72 75 72 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGT</italic>
ORs and 95% CI for coronary heart disease and the M235T polymorphism in AGT gene under different genetic models.
###end title 61
###begin p 62
The additive genetic model assumes that there is a linear gradient in risk between the MM, MT and TT genotypes (MM genotype baseline). This is equivalent to a comparison of the T allele versus the M allele (baseline).
###end p 62
###begin title 63
###xml 37 40 37 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGT</italic>
Studies of the M235T polymorphism in AGT gene and risk of coronary heart disease under additive model grouped by study characteristics.
###end title 63
###begin title 64
Meta-regression
###end title 64
###begin p 65
###xml 158 159 156 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 213 214 209 210 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 781 784 774 777 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Het</sub>
###xml 780 784 773 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P<sub>Het</sub></italic>
###xml 797 798 788 789 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 865 868 853 856 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Het</sub>
###xml 864 868 852 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P<sub>Het</sub></italic>
###xml 881 882 867 868 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1034 1037 1017 1020 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Het</sub>
###xml 1033 1037 1016 1020 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P<sub>Het</sub></italic>
###xml 1050 1051 1031 1032 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1136 1139 1117 1120 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Het</sub>
###xml 1135 1139 1116 1120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P<sub>Het</sub></italic>
###xml 1152 1153 1131 1132 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1180 1183 1159 1162 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Het</sub>
###xml 1179 1183 1158 1162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P<sub>Het</sub></italic>
###xml 1196 1197 1173 1174 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1243 1246 1220 1223 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Het</sub>
###xml 1242 1246 1219 1223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P<sub>Het</sub></italic>
###xml 1259 1260 1234 1235 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1292 1295 1267 1270 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Het</sub>
###xml 1291 1295 1266 1270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P<sub>Het</sub></italic>
###xml 1308 1309 1281 1282 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1346 1349 1319 1322 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Het</sub>
###xml 1345 1349 1318 1322 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P<sub>Het</sub></italic>
###xml 1362 1363 1333 1334 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1399 1402 1370 1373 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Het</sub>
###xml 1398 1402 1369 1373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P<sub>Het</sub></italic>
###xml 1415 1416 1384 1385 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1442 1445 1411 1414 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Het</sub>
###xml 1441 1445 1410 1414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P<sub>Het</sub></italic>
###xml 1458 1459 1425 1426 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1693 1696 1660 1663 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Het</sub>
###xml 1692 1696 1659 1663 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P<sub>Het</sub></italic>
###xml 1709 1710 1674 1675 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1832 1833 1795 1796 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1851 1854 1814 1817 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Het</sub>
###xml 1850 1854 1813 1817 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P<sub>Het</sub></italic>
###xml 1886 1889 1849 1852 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Het</sub>
###xml 1885 1889 1848 1852 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P<sub>Het</sub></italic>
###xml 1930 1933 1893 1896 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Het</sub>
###xml 1929 1933 1892 1896 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P<sub>Het</sub></italic>
###xml 2247 2248 2208 2209 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 2266 2269 2227 2230 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Het</sub>
###xml 2265 2269 2226 2230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P<sub>Het</sub></italic>
First, an empty regression was run with only the log of the effect estimate of pooled studies under the additive model to determine the baseline value for tau2, an estimate of between-study variation (baseline tau2 = 0.025). Next, single covariates were added in a series of univariate models. We performed the regression analysis for ten pre-defined potential sources of heterogeneity, including ethnicity, sex, mean age of cases, study size, case definition, source of controls, HWE-violation, blinding in genotyping, performing a sub-sample regenotyping, and matching (we hypothesized that studies that used matching might produce more conservative estimates of association). Univariate regression analyses showed that violation of HWE (beta coefficient = 0.27 (0.06 to 0.48); PHet = 0.015, tau2 = 0.019), the mean age of cases (beta = -0.01 (-0.02 to 0.0008); PHet = 0.066, tau2 = 0.024), and the method of case definition, clinically diagnosed CHD versus WHO criteria adjusted for other definitions (beta = 0.26 (0.02 to 0.50); PHet = 0.038, tau2 = 0.020), were significant sources of heterogeneity among studies. The study size (PHet = 0.241, tau2 = 0.024), the ethnicity (PHet = 0.591, tau2 = 0.025), the male percentage in the study (PHet = 0.701, tau2 = 0.029), blinded genotyping (PHet = 0.890, tau2 = 0.026), sub-sample regenotyping (PHet = 0.131, tau2 = 0.023), the source of controls (PHet = 0.640, tau2 = 0.025), and matching (PHet = 0.942, tau2 = 0.026) were not significant sources of heterogeneity among studies. Violation of HWE in multivariable regression analysis remained a statistically significant source of heterogeneity after adjustment for the effect of study size (PHet = 0.031, tau2 = 0.020). Adding the mean age of cases and method of case definition to the model with violation of HWE decreased the tau2 value to 0.017 (PHet = 0.073 for violation of HWE, PHet = 0.057 for the mean age of cases, and PHet = 0.162 for clinically diagnosed CHD). It also showed that the effect of method of case definition on the variation among the studies was through the effect of the mean age on the heterogeneity and not as an independent factor. A model that included only violation of HWE and the mean age of cases reduced the tau2 value to 0.018 (PHet = 0.019, and 0.052, respectively).
###end p 65
###begin title 66
Sensitivity Analysis
###end title 66
###begin p 67
###xml 116 123 116 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002533-t006">Table 6</xref>
First, the influence of deviation from the HWE on effect estimates was examined by using HWE-deviated adjusted ORs. Table 6 presents the genotype-based contrasts with corrected ORs, as well as the allele-based contrast. After adjustment, a smaller overall effect was seen under the additive, dominant, and pairwise comparisons. Moreover, after adjustment, the previously significant association under the additive model, as well as the TT vs. MM comparison, was no longer statistically significant. The association under the recessive model still remained significant.
###end p 67
###begin title 68
ORs and 95% CI after adjustment for HWE-deviation under different genetic models.
###end title 68
###begin p 69
###xml 0 8 0 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002533-g003">Figure 3</xref>
###xml 366 367 366 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 634 642 634 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002533-g004">Figure 4</xref>
Figure 3 shows a funnel plot in which the log of the OR of CHD risk under the additive genetic model was plotted against the standard error of the log of the OR in each study. The funnel plot for the overall results was substantially asymmetric for small negative studies. Moreover, tests for potential publication bias (The Egger's test and the Begg-Mazumdar test; P-values equal to 0.066 and 0.074, respectively) suggested the presence of a publication bias. By using the trim and fill method, we showed that, if the publication bias was the only source of the funnel plot asymmetry, it needed seven more studies to be symmetrical (Figure 4).
###end p 69
###begin title 70
Begg's funnel plot with pseudo 95% confidence limits under the additive genetic model.
###end title 70
###begin p 71
The size of the circle is proportional to the weight of the study.
###end p 71
###begin title 72
Filled Begg's funnel plot with pseudo 95% confidence limits under the additive genetic model.
###end title 72
###begin p 73
Red squares are missed studies due to publication bias.
###end p 73
###begin title 74
Discussion
###end title 74
###begin title 75
Prospect-EPIC study
###end title 75
###begin p 76
###xml 135 138 135 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGT</italic>
###xml 1046 1050 1046 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Seminara1">[59]</xref>
###xml 37 42 <span type="species:ncbi:9606">women</span>
In this prospective study of healthy women aged 49 to 70 years, we investigated the relationship between the M235T polymorphism in the AGT gene and risk of AMI and CHD later in life. Under the additive genetic model, increased risks, albeit not statistically significant, were found for the incidence of AMI and CHD, which did not alter after adjustment. Likewise, we did not find a clear association between the variant and risk of CHD or AMI using different genetic models. This may be explained by: (i) the absence of a biological effect, (ii) the presence of real genetic heterogeneity according to ethnic background, or (iii) failure to detect a small effect because the epidemiologic risk for an individual genetic variant is likely to be small and a large sample size is needed for adequate statistical power. It has been commonly proposed that, as well as a need for much larger and more rigorous studies those that are currently used, there is a greater need for international collaborations, particularly for a complex disease like CHD [59].
###end p 76
###begin title 77
Strengths and limitations
###end title 77
###begin p 78
###xml 196 200 196 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Prentice1">[17]</xref>
###xml 1532 1535 1532 1535 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGT</italic>
###xml 104 116 <span type="species:ncbi:9606">participants</span>
###xml 1748 1753 <span type="species:ncbi:9606">women</span>
###xml 1794 1797 <span type="species:ncbi:9606">men</span>
In our study, the data collection was prospective, before the diagnosis of AMI or CHD and equal for all participants. This ensures that the cases and the randomly selected controls are comparable [17]. For a multifactorial trait, like CHD, this provides a valid approach to evaluate the relationship between genetic factors and the risk of AMI and CHD, while taking into account co-existing and risk-modifying factors. In this study, prevalent cases of CHD were excluded from the analyses to prevent introducing bias due to potentially selective survival. The Prospect study was a population-based cohort, which makes it less susceptible to selection bias. Additional strengths were the comprehensiveness of our data and sample collection, as well as the morbidity and mortality follow-up for the entire cohort through linkage with nation-wide registries. The case-cohort design of the study combined the advantages of cohort studies (multiple outcomes and time-dependent covariates) with those of case-control analyses (fewer subjects); thus, it was more efficient than cohort studies. Classical case-control studies might be affected by selection bias since only non-fatal cases can be included, which was not the case in this study because of our endpoint definition. Moreover, we did not have misclassification of exposure (genotypes), which, when present, generally lead to a bias toward the null because we used standard laboratory protocols, performed a random double-check to detect potential genotyping errors, and had our AGT genotypes in Hardy-Weinberg equilibrium. The limitations of this study were the relatively short period of follow-up and the small number of cases. Moreover, because this cohort was exclusively composed of Dutch women, these results cannot be generalized to men or other ethnic groups, for whom the rates of the events or the allele frequency are known to differ.
###end p 78
###begin title 79
Meta-Analysis
###end title 79
###begin p 80
###xml 193 196 193 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGT</italic>
###xml 706 709 706 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGT</italic>
###xml 972 979 972 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002533-t005">Table 5</xref>
###xml 1081 1088 1081 1088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002533-t006">Table 6</xref>
###xml 120 125 <span type="species:ncbi:9606">women</span>
The current meta-analysis, which includes new data from a prospective study in a large population-based cohort of Dutch women, represents a comprehensive evaluation of the M235T variant of the AGT gene in CHD risk. Although a pooled per-allele OR was suggestive of a modest increase in the risk of CHD of 1.08 (95% CI, 1.01 to 1.15), the robustness of this summary estimate is uncertain. First, in the pre-specified sub-groups analyses in the meta-analysis, larger studies, those with validated genotyping quality controls, and studies that used standardized criteria for case definition did not provide strong evidence for a positive statistically significant association between the M235T variant of the AGT gene and CHD risk. Second, the meta-regression analysis revealed that the HWE violation was a significant source of the moderate to large heterogeneity in the meta-analysis. Taking violation of HWE into account in the meta-analysis decreased the overall effect (Table 5). Third, the previous result was confirmed by using HWE-deviation adjusted ORs in the meta-analysis (Table 6). Moreover, there was evidence for publication bias in the meta-analysis. Taken together, these findings point to a violation of HWE and publication biases as the potential explanations for the results observed in the meta-analysis.
###end p 80
###begin p 81
###xml 1234 1238 1234 1238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Buraczynska1">[33]</xref>
###xml 1755 1759 1755 1759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Sethi2">[14]</xref>
###xml 1088 1094 <span type="species:ncbi:9606">people</span>
Some aspects of the current meta-analysis need to be considered to appreciate the findings. First, it might not be very practical to adjust for violation of HWE in the studies that mentioned that the violation is not due to genotyping errors. However, in the current meta-analysis, the HWE-violated studies that were included in the pooled estimate did not provide any reason for the violation. Therefore, we performed sensitivity analyses by using HWE-adjusted ORs and corresponding variances. Thereafter, a smaller overall effect was seen under most of the genetic models. Second, the power of tests for HWE and the power to detect genotyping errors are low. Therefore, the inability to detect a deviation from the HWE does not mean that there is no deviation, nor does it rule out the presence of genotyping errors, especially for small sample sizes. Third, our meta-analysis was based on published studies and we did not have access to the original data. However, it could be possible that an association between the genotype and disease exists in certain contexts rather than in all people studied. For example, a case-control study showed that the TT genotype was associated with an increased risk of CHD and MI only in smokers [33]. Finally, in all meta-analyses of gene-disease association studies, the inclusion criteria of cases and controls can be a potentially confounding factor. In this meta-analysis, cases were well defined and the source of controls was not a significant source of variation. However, the advantages of this study were the large sample size of the meta-analysis of 38 studies with 13284 cases and 18722 controls, which was twice the number of studies and sample sizes that had been reported in the previous meta-analysis [14], the exploration of potential sources of heterogeneity in the meta-analysis, and the evaluation of the association under different modes of inheritance.
###end p 81
###begin p 82
###xml 315 319 315 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Trikalinos1">[20]</xref>
###xml 321 325 321 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Salanti1">[60]</xref>
###xml 779 783 779 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Little1">[61]</xref>
###xml 1563 1567 1563 1567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Xu1">[62]</xref>
Approximately 10% of gene-disease association studies are affected by statistically significant deviation from HWE, which could result from genotyping error, chance, inbreeding, non-random mating, differential survival of marker carriers, genetic drift, population stratification, or a combination of these reasons [20], [60]. Of these, genotyping error could be avoided by using standard genotyping methods and performing quality assessment. It has been recommended that authors specify the quality measures for the genotyping analysis, such as the blinding of laboratory staff to the donor subjects and hypotheses being investigated, procedures for establishing duplicates, degree of reproducibility between quality control replicates, and the inspection for conformity to HWE [61]. In the current meta-analysis, in studies where the blinding of genotyping staff was not reported, a statistically significant increased risk of CHD was found, while those that used blinding methods did not find a significant association. Moreover, for studies without regenotyping of a random sub-sample, a significant increase in CHD risk was found, but not for studies that performed regenotyping. Although overlapping confidence intervals for before-mentioned risks indicate caution in any interpretations, no report on blinding and regenotyping can point towards an uncertainty in quality control of genotyping in these studies. However, violation of HWE, which tends to inflate the chance of a false positive association, may be the strongest indicator of genotyping error [62].
###end p 82
###begin p 83
###xml 327 331 327 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Ntzani1">[63]</xref>
###xml 598 602 598 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Ntzani1">[63]</xref>
###xml 2136 2140 2136 2140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002533-Wacholder1">[64]</xref>
Violation of HWE cannot solely explain the observed between-study variation in gene-disease association studies. The large between-study heterogeneity presented in most meta-analyses could be due to true heterogeneity (i.e., racial differences or differences in gene-environment interactions among various populations) or bias [63]. Bias, which could invalidate the results of the studies, should, therefore, be explored in detail. Biological plausibility, publication bias, selection bias, biased definition of cases, biased selection of controls, and population stratification should be assessed [63]. In this meta-analysis, we found strong evidence for publication bias. This is said to occur when the chance of the publication of a smaller study increases when it shows a stronger effect. Further exploration for sources of biases among studies showed that the selection of controls was not biased. However, using different case definitions resulted in a significant difference in the risk of CHD between those studies using WHO criteria and those using clinically diagnoses of CHD. Studies using definition of cases based on coronary angiography or based on WHO criteria had the same results. Considering a multivariate model in the meta-regression results, case definition was not a significant source of bias in the meta-analysis, while the different mean age of cases and violation of HWE were significant sources of heterogeneity. Since increasing age is a risk factor for CHD and the mean age of cases in the included studies ranged from 42 to 67 years, it is more likely that the studies with older individuals would show a stronger effect and produce heterogeneity. As case-parental controls, or other family-based designs, and genomic controls, using unlinked genetic markers which have no effect on the risk of CHD, were not available to evaluate the potential problem of population stratification among the studies, we presented effect estimates by different ethnic groups. However, there is controversy about the potential importance of population stratification for genetic-association studies using unrelated subjects [64].
###end p 83
###begin p 84
###xml 143 146 143 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AGT</italic>
In conclusion, the present meta-analysis, including our own data, indicated that, although a weak association between the M235T variant in the AGT gene and CHD was found, the relevance of this weakly positive overall association remains uncertain because it may be due to various residual biases. Moderate to large heterogeneity was identified between studies, and violation of HWE and the mean age of cases were statistically significant sources of the observed variation.
###end p 84
###begin p 85
###xml 23 35 <span type="species:ncbi:9606">participants</span>
We are grateful to the participants of the Prospect-EPIC study. We would like to thank all field workers and laboratory technicians for their skillful contributions to the data collection.
###end p 85
###begin title 86
References
###end title 86
###begin article-title 87
###xml 19 24 <span type="species:ncbi:9606">human</span>
Molecular basis of human hypertension: role of angiotensinogen.
###end article-title 87
###begin article-title 88
###xml 45 50 <span type="species:ncbi:9606">human</span>
Linkage of the angiotensinogen gene locus to human essential hypertension in African Caribbeans.
###end article-title 88
###begin article-title 89
Genotype-phenotype relationships for the renin-angiotensin-aldosterone system in a normal population.
###end article-title 89
###begin article-title 90
M235T angiotensinogen gene polymorphism and cardiovascular renal risk.
###end article-title 90
###begin article-title 91
Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening?
###end article-title 91
###begin article-title 92
Associations between candidate loci angiotensin-converting enzyme and angiotensinogen with coronary heart disease and myocardial infarction: the NHLBI Family Heart Study.
###end article-title 92
###begin article-title 93
###xml 93 101 <span type="species:ncbi:9606">patients</span>
Homozygosity for angiotensinogen 235T variant increases the risk of myocardial infarction in patients with multi-vessel coronary artery disease.
###end article-title 93
###begin article-title 94
Association of angiotensinogen M235T and A(-6)G gene polymorphisms with coronary heart disease with independence of essential hypertension: the PROCAGENE study. Prospective Cardiac Gene.
###end article-title 94
###begin article-title 95
Angiotensinogen M235T polymorphism is associated with coronary artery disease severity.
###end article-title 95
###begin article-title 96
Renin-angiotensin system gene polymorphisms and premature coronary heart disease.
###end article-title 96
###begin article-title 97
Coronary heart disease, hypertension, and angiotensinogen gene variants in Indian population.
###end article-title 97
###begin article-title 98
Angiotensinogen single nucleotide polymorphisms, elevated blood pressure, and risk of cardiovascular disease.
###end article-title 98
###begin article-title 99
Gene polymorphisms of the renin-angiotensin system in relation to hypertension and parental history of myocardial infarction and stroke: the PEGASE study. Projet d'Etude des Genes de l'Hypertension Arterielle Severe a moderee Essentielle.
###end article-title 99
###begin article-title 100
Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: a meta-analysis.
###end article-title 100
###begin article-title 101
Prospect-EPIC Utrecht: study design and characteristics of the cohort population. European Prospective Investigation into Cancer and Nutrition.
###end article-title 101
###begin article-title 102
T64A polymorphism in beta3-adrenergic receptor gene (ADRB3) and coronary heart disease: a case-cohort study and meta-analysis.
###end article-title 102
###begin article-title 103
A case-cohort design for epidemiologic cohort studies and disease prevention trials.
###end article-title 103
###begin article-title 104
A multilocus genotyping assay for candidate markers of cardiovascular disease risk.
###end article-title 104
###begin article-title 105
Analysis of case-cohort data: a comparison of different methods.
###end article-title 105
###begin article-title 106
Impact of violations and deviations in Hardy-Weinberg equilibrium on postulated gene-disease associations.
###end article-title 106
###begin article-title 107
Measuring inconsistency in meta-analyses.
###end article-title 107
###begin article-title 108
ACE gene polymorphism in cardiovascular disease: meta-analyses of small and large studies in whites.
###end article-title 108
###begin article-title 109
Association between the eNOS (Glu298Asp) and the RAS genes polymorphisms and premature coronary artery disease in a Turkish population.
###end article-title 109
###begin article-title 110
Both alleles of the M235T polymorphism of the angiotensinogen gene can be a risk factor for myocardial infarction.
###end article-title 110
###begin article-title 111
Multi-locus candidate gene polymorphisms and risk of myocardial infarction: a population-based, prospective genetic analysis.
###end article-title 111
###begin article-title 112
Interaction between gene polymorphisms of renin-angiotensin system and metabolic risk factors in premature myocardial infarction.
###end article-title 112
###begin article-title 113
Molecular variants of the renin-angiotensin system components in the Slovak population.
###end article-title 113
###begin article-title 114
Polymorphism in the angiotensinogen gene, hypertension, and ethnic differences in the risk of recurrent coronary events.
###end article-title 114
###begin article-title 115
Angiotensinogen mutations and risk for ischemic heart disease, myocardial infarction, and ischemic cerebrovascular disease. Six case-control studies from the Copenhagen City Heart Study.
###end article-title 115
###begin article-title 116
Genotypic interactions of renin-angiotensin system genes in myocardial infarction.
###end article-title 116
###begin article-title 117
Synergistic effect between apolipoprotein E and angiotensinogen gene polymorphisms in the risk for early myocardial infarction.
###end article-title 117
###begin article-title 118
###xml 162 170 <span type="species:ncbi:9606">patients</span>
Angiotensinogen Met235Thr polymorphism, angiotensin-converting enzyme inhibitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients.
###end article-title 118
###begin article-title 119
Renin-angiotensin system gene polymorphisms: assessment of the risk of coronary heart disease.
###end article-title 119
###begin article-title 120
A polymorphism of angiotensinogen gene codon 174 and coronary artery disease in Japanese subjects.
###end article-title 120
###begin article-title 121
Angiotensin I converting enzyme, angiotensin II type 1 receptor and angiotensinogen polymorphisms and early myocardial infarction in Turkish population.
###end article-title 121
###begin article-title 122
Searching for a better assessment of the individual coronary risk profile. The role of angiotensin-converting enzyme, angiotensin II type 1 receptor and angiotensinogen gene polymorphisms.
###end article-title 122
###begin article-title 123
The genotype interactions of methylenetetrahydrofolate reductase and renin-angiotensin system genes are associated with myocardial infarction.
###end article-title 123
###begin article-title 124
Gene-gene interaction in the RAS system in the predisposition to myocardial infarction in elder population of St. Petersburg (Russia).
###end article-title 124
###begin article-title 125
Associations of angiotensinogen gene mutations with hypertension and myocardial infarction in a gulf population.
###end article-title 125
###begin article-title 126
Angiotensinogen T174M and M235T gene polymorphisms are associated with the extent of coronary atherosclerosis.
###end article-title 126
###begin article-title 127
Relationship of venous thromboembolism and myocardial infarction with the renin-angiotensin system in African-Americans.
###end article-title 127
###begin article-title 128
###xml 129 132 <span type="species:ncbi:9606">men</span>
Lack of association between variants of the angiotensinogen gene and the risk of coronary artery disease in middle-aged Japanese men.
###end article-title 128
###begin article-title 129
Molecular variant of angiotensinogen gene is associated with coronary atherosclerosis.
###end article-title 129
###begin article-title 130
Enhanced predictability of myocardial infarction in Japanese by combined genotype analysis.
###end article-title 130
###begin article-title 131
Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease.
###end article-title 131
###begin article-title 132
Angiotensinogen and angiotensin-I converting enzyme gene polymorphisms and the risk of coronary artery disease in Chinese.
###end article-title 132
###begin article-title 133
###xml 95 100 <span type="species:ncbi:9606">women</span>
ACE-DD genotype is associated with the occurrence of acute coronary syndrome in postmenopausal women.
###end article-title 133
###begin article-title 134
Analysis of several hundred genetic polymorphisms may improve assessment of the individual genetic burden for coronary artery disease.
###end article-title 134
###begin article-title 135
Renin-angiotensin system and associated gene polymorphisms in myocardial infarction in young South African Indians.
###end article-title 135
###begin article-title 136
A common variant of the angiotensinogen gene and the risk of coronary artery disease in a German population.
###end article-title 136
###begin article-title 137
Association of angiotensinogen haplotypes with angiotensinogen levels but not with blood pressure or coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health Study.
###end article-title 137
###begin article-title 138
###xml 87 90 <span type="species:ncbi:9606">men</span>
Angiotensinogen gene polymorphism is associated with insulin resistance in nondiabetic men with or without coronary heart disease.
###end article-title 138
###begin article-title 139
Genotypes and haplotypes predisposing to myocardial infarction: a multilocus case-control study.
###end article-title 139
###begin article-title 140
Renin-angiotensin system gene polymorphisms and coronary artery disease in a large angiographic cohort: detection of high order gene-gene interaction.
###end article-title 140
###begin article-title 141
###xml 83 91 <span type="species:ncbi:9606">patients</span>
Relationship of polymorphisms in the renin-angiotensin system and in E-selectin of patients with early severe coronary heart disease.
###end article-title 141
###begin article-title 142
Renin-angiotensin system polymorphisms and coronary events in familial hypercholesterolemia.
###end article-title 142
###begin article-title 143
Angiotensinogen M235T polymorphism is associated with plasma angiotensinogen and cardiovascular disease.
###end article-title 143
###begin article-title 144
Absence of association of angiotensinogen gene T235 allele with increased risk of coronary heart disease in Japanese.
###end article-title 144
###begin article-title 145
###xml 29 34 <span type="species:ncbi:9606">human</span>
The emergence of networks in human genome epidemiology: challenges and opportunities.
###end article-title 145
###begin article-title 146
Hardy-Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power.
###end article-title 146
###begin article-title 147
Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations.
###end article-title 147
###begin article-title 148
Positive results in association studies are associated with departure from Hardy-Weinberg equilibrium: hint for genotyping error?
###end article-title 148
###begin article-title 149
Genetic effects versus bias for candidate polymorphisms in myocardial infarction: case study and overview of large-scale evidence.
###end article-title 149
###begin article-title 150
Counterpoint: bias from population stratification is not a major threat to the validity of conclusions from epidemiological studies of common polymorphisms and cancer.
###end article-title 150
###begin p 151
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 151
###begin p 152
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: The first author has been supported by a grant from the Iranian Ministry of Health and Medical Education (FN12265). The Prospect-EPIC study was funded by "Europe Against Cancer" Programme of the European Commission (SANCO). There are no financial or other relationships that might lead to a conflict of interest.
###end p 152

